Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D2 | Q14995 | 2/20 | 0.73 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 2/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
| ▸ | TAF1 | P21675 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29906510 | 1.00 | NR1D2 (0.73) | NR1D2NR1D1ATMHTR1ASLC6A4 | |
| SCHEMBL17982824 | 0.99 | NR1D2 (0.71) | NR1D2NR1D1ATMHTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL16638032 | 0.99 | NR1D2 (0.71) | NR1D2NR1D1ATMHTR1ASLC6A4 | |
| SCHEMBL18021971 | 0.91 | NR1D2 (0.61) | NR1D2NR1D1ATMHTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL17982785 | 0.90 | NR1D2 (0.60) | NR1D2NR1D1ATMHTR1ASLC6A4 | |
| SCHEMBL26556315 | 0.88 | NR1D2 (0.68) | NR1D2NR1D1HTR1ASLC6A4CARM1 | |
| SCHEMBL17982793 | 0.88 | NR1D2 (0.58) | NR1D2NR1D1ATMCYP2C9CYP2C19 | |
| SCHEMBL18021965 | 0.87 | NR1D2 (0.55) | NR1D2NR1D1ATMCYP2C9CYP2C19 | |
| SCHEMBL17982805 | 0.87 | NR1D2 (0.56) | NR1D2NR1D1HTR1ASLC6A4 | |
| SCHEMBL17982833 | 0.87 | NR1D2 (0.56) | NR1D2NR1D1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110709507-A | Natural killer cell | 帝国理工学院 | 2020-01-17 | — | — | CN | claimed |
| EP-3055293-B1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-12-06 | — | — | EP | claimed |
| US-20230330145-A1 | NATURAL KILLER CELLS | IMPERIAL COLLEGE INNOVATION LIMITED (GB) | 2023-10-19 | — | — | US | disclosed |
| US-11566226-B2 | Natural killer cells | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-01-31 | — | — | US | disclosed |
| US-11559547-B2 | Natural killer cells | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-01-24 | — | — | US | disclosed |
| US-20230002732-A1 | NATURAL KILLER CELLS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20200032210-A1 | NATURAL KILLER CELLS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2020-01-30 | — | — | US | disclosed |
| CN-110709507-A | Natural killer cell | 帝国理工学院 | 2020-01-17 | — | — | CN | disclosed |
| US-9949968-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-04-24 | — | — | US | disclosed |
| US-9949968-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-04-24 | — | — | US | disclosed |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-05-18 | — | — | US | disclosed |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-05-18 | — | — | US | disclosed |
| US-9611245-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-04-04 | — | — | US | disclosed |
| US-9611245-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-04-04 | — | — | US | disclosed |
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330145-A1 | NATURAL KILLER CELLS | PBK, NFATC1, IKZF2 | NR1D2 2428/4885NR1D1 1774/4885ATM 3380/4885 |
| US-11559547-B2 | Natural killer cells | PBK, NFATC1, IKZF2 | NR1D2 2428/4885NR1D1 1774/4885ATM 3380/4885 |
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | NR1D1, NR1I3, BCOR | NR1D2 9/4885NR1D1 1/4885ATM 2349/4885 |
| US-20200032210-A1 | NATURAL KILLER CELLS | PBK, NFATC1, IKZF2 | NR1D2 2428/4885NR1D1 1774/4885ATM 3380/4885 |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | NR1D1, NR1I3, BCOR | NR1D2 9/4885NR1D1 1/4885ATM 2449/4885 |
| US-11566226-B2 | Natural killer cells | PBK, NFATC1, IKZF2 | NR1D2 2428/4885NR1D1 1774/4885ATM 3380/4885 |
| US-20230002732-A1 | NATURAL KILLER CELLS | PBK, NFATC1, IKZF2 | NR1D2 2428/4885NR1D1 1774/4885ATM 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.